RAREUltragenyx Pharmaceutical Inc
RARE
Ultragenyx Pharmaceutical Inc2,862
Mkt Cap
$2.25BVolume
1.55M52W High
$42.3752W Low
$18.29PE Ratio
-3.99RARE Fundamentals
Price
$23.30Prev Close
$23.91Open
$24.0250D MA
$22.20Beta
1.10Avg. Volume
2.27MEPS (Annual)
-$5.83P/B
-28.08Rev/Employee
$490,882.57$2,833.80
Ultragenyx Pharmaceutical Inc. $RARE Stock Position Cut by SG Americas Securities LLC
SG Americas Securities LLC trimmed its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 74.3% during the fourth quarter, according to its most recent filing with the...
MarketBeat·2d ago
Rep. Gilbert Ray Cisneros, Jr. Buys Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares
Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Ultragenyx Pharmaceutical stock on March 3rd...
MarketBeat·3d ago
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Lags Revenue Estimates
Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of -4.22% and -57.21%, respectively, for the quarter ended February 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5d ago
RARE Rises as FDA Accepts Resubmitted BLA for Sanfilippo Syndrome
Ultragenyx Pharmaceutical jumps 5% as the FDA accepts UX111 BLA resubmission, setting up a September 2026 decision for a potential first treatment for MPS IIIA.
Zacks·7d ago
RARE FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ultragenyx Pharmaceutical Inc (Ultragenyx or the Company) (NASDAQ: RARE) and reminds investors...
Business Wire·7d ago
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc...
PR Newswire·7d ago
Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE
Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact...
PR Newswire·7d ago
Aberdeen Group plc Buys 496,295 Shares of Ultragenyx Pharmaceutical Inc. $RARE
Aberdeen Group plc boosted its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 51.0% during the 4th quarter, according to its most recent 13F filing with the Securities and...
MarketBeat·8d ago
RARE SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
RARE SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 RARE SHAREHOLDER ALERT: Faruqi & Faruqi, LLP...
PR Newswire·9d ago
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eighteen ratings firms that are presently covering the firm...
MarketBeat·9d ago
<
1
2
...
>